Prior Labs’ Post

Read how BostonGene is using #TabPFN to improve patient outcomes and accelerate drug discovery! By integrating TabPFN into its advanced ML platform, BostonGene successfully overcame significant challenges posed by limited data availability and complex, high-dimensional immune cell profiling datasets. BostonGene is a pioneer in precision medicine that partners with institutions such as Takeda, BeiGene and MD Anderson Cancer Center. ✔️ Developed a highly accurate TabPFN classifier (90% accuracy) capable of distinguishing cancer patients from healthy individuals using only peripheral blood immune profiles—without needing tumor data. ✔️ Achieved 90% faster ML workflows by eliminating manual hyperparameter tuning. ✔️ Enabled oncologists to more accurately personalize immunotherapy regimens, significantly enhancing patient outcomes. Michael Goldberg, PhD, VP R&D at BostonGene, stated: “Accurately classifying cancer patients based on peripheral immune cell distribution was remarkably challenging—TabPFN made it a reality.” Arseniy Sokolov, former Data Scientist at BostonGene, further highlighted: “TabPFN eliminated tedious hyperparameter tuning, enabling us to focus on core scientific questions rather than technical optimization. Our model development was accelerated dramatically while maintaining outstanding classification performance.” Explore the full story and learn how TabPFN is redefining precision medicine. Thanks to the BostonGene team for their contributions! #PrecisionMedicine #ImmunoOncology #MachineLearning #CancerResearch #ClinicalInnovation #DrugDiscovery #BiomarkerDiscovery